RESET PLATFORM
Junevity’s RESET platform is the first to use large-scale human data and AI to develop novel siRNA therapeutics targeting transcription factors.
Transcriptional dysregulation drives disease
PROBLEM
Diseases related to longevity and aging see profound transcriptional dysregulation, which is often overlooked in drug discovery due to its complexity.
Cell Reset
SOLUTION
Based on Dr. Janine Sengstack’s breakthrough work at UCSF, we identify pathways that become overactive with age and disease. Then, we develop siRNA therapeutics to knock down the transcription factors regulating these pathways, resetting cell health.
This approach unlocks new therapeutics for many diseases related to longevity and aging.
HOW WE DO IT
RESET Platform
RESET is a therapeutic discovery platform combining large-scale human data, a modern wet lab and AI / ML. Developed originally at UCSF from 2017-2023, Junevity has since expanded its capabilities to develop novel medicines.
Our platform is the first to focus on siRNA for transcription factors, an under-explored therapeutic opportunity only possible with today’s technology.
Partnering
Junevity collaborates with pharmaceutical companies to develop new cell reset siRNA therapeutics.
If you would like to learn more, you can contact us here.
